Oxcarbazepine

Authors: Beydoun A.; Kutluay E.

Source: Expert Opinion on Pharmacotherapy, Volume 3, Number 1, 1 January 2002 , pp. 59-71(13)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $99.00 plus tax (Refund Policy)

Abstract:

Oxcarbazepine (OXC) (Trileptal®, Novartis) is one of the recently introduced anti-epileptic drugs (AEDs) in the US. This drug has demonstrated efficacy as adjunctive therapy in adults and children, and as monotherapy in adults for the treatment of seizures of partial onset. There is also convincing evidence of its efficacy in patients with newly diagnosed and refractory trigeminal neuralgia. In addition, the initial efficacy results of oxcarbazepine in other neuropathic pain conditions and in bipolar disorders are encouraging. In this review, recommendations on the optimal clinical use of OXC are given based on its pharmacokinetic profile, efficacy and tolerability in those various conditions.

Keywords: bipolar disorders; efficacy; epilepsy; mania; neuropathic pain; oxcarbazepine; partial seizures; pharmacokinetics; safety; tolerability; trigeminal neuralgia

Document Type: Drug Evaluation

Publication date: 2002-01-01

More about this publication?
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page